Saturday 17 October 2026 Export TRIB’s income statement to Excel — free account

Trinity Biotech PLC

Trinity Biotech PLC’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, down 28.9% from fiscal 2024. In the quarter to March 2026, revenue grew 43.3%, EPS grew 52.1%, free cash flow grew 75.2% and total debt rose 29.9%, each against the same quarter a year earlier. Dividend growth for five consecutive years.

8.03 0.10 +1.26%

Follow TRIB

Alert me

Market cap: $5.1M
P/E: 0.0×
Fwd P/E: −1.3×
Dividend yield: —
F-score: 4/9
Altman Z: −2.78
Beneish M: −4.29
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 1.77%

Capital & Financial Ratios $m

Market Cap 5.08

Revenue 47.06

Net Income (32.97)

Free Cash Flow (4.28)

Net Debt 135.05

Current Ratio 0.22

Debt/Equity (1.81)

P/E ratio 0.00

Fwd P/E (1.33)

P/S ratio 0.11

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (0.60%)

Next Y EPS Growth 38.42%

Next Y revenue growth 77.00%

Next 5Y EPS Growth 53.32%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.03%

10-year low 10-year high

EV/Sales against its own 10 years 91.96%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	4	5	5	2
Receivables	14	16	11	11
Inventory	20	19	19	18
Other	2	1	0	1
	39	41	36	31

	2023	2024	2025	Q'26
Payables	13	27	30	30
ST’ Debt	—	—	108	110
Other	0	3	1	1
	15	32	141	144

Compound Annual Growth %

	10y	5y	3y
Sales	(7.94%)	(15.56%)	(11.20%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	11	—	—	—	—
’25	8	11	14	11	44
’24	15	16	15	16	62
’23	15	14	15	13	57
’22	16	15	16	16	63
’21	26	26	22	20	93
’20	21	16	32	33	102

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	—	—	—	—
’25	(3)	(2)	0	(1)	(6)
’24	(3)	(1)	(4)	3	(4)
’23	(3)	(4)	(5)	0	(12)
’22	(1)	(2)	1	2	(1)
’21	6	1	2	4	13
’20	2	3	7	12	24

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	—	—	—	—
’25	(5)	(6)	(1)	(2)	(12)
’24	(4)	(4)	(6)	1	(14)
’23	(3)	(5)	(5)	(1)	(14)
’22	(3)	(4)	(1)	1	(7)
’21	4	(1)	0	2	5
’20	(1)	1	5	9	14

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(6.91)	—	—	—	—
’25	(14.41)	(9.61)	(8.41)	(27.03)	(60.06)
’24	(11.11)	(21.32)	(13.81)	(38.44)	(53.15)
’23	(22.52)	(24.02)	(27.03)	(21.62)	(94.29)
’22	(75.08)	(43.54)	(36.04)	(39.04)	(183.18)
’21	10.62	(6.01)	13.51	(9.01)	6.01
’20	(6.01)	(8.49)	48.05	(46.55)	(3.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	864.00	633.00	319.50	94.50	84.00	207.00	129.00	55.50	22.50	14.40	Analyst estimates 2026–2028 Powerpack
	High	2,052.00	1,080.00	981.00	504.00	741.00	1,023.00	232.50	186.00	106.50	103.20
People
People	Employees	582	556	575	579	543	477	398	380	401	287
	Revenue/emp, $m	0.17	0.18	0.17	0.16	0.19	0.19	0.16	0.15	0.15	0.15
Income, $m
Income, $m	Revenue	100	99	97	90	102	93	63	57	62	44
	Gross margin, %	43.65	42.25	42.72	42.15	47.64	40.96	27.62	34.22	34.83	38.57
	EBT	(42)	(40)	(23)	(30)	(7)	1	(44)	(37)	(31)	(37)
	EBT margin, %	(42.30)	(40.22)	(23.89)	(33.17)	(6.50)	0.81	(70.02)	(64.98)	(49.92)	(84.91)
	Net income	(101)	(40)	(22)	(29)	(6)	1	(41)	(24)	(32)	(37)
	Depreciation	6	5	4	5	3	3	2	2	2	3
Per share, $
Per share, $	Revenue	651.48	688.47	697.09	648.28	732.61	638.06	278.24	222.96	102.92	70.78
	Earnings	(657.66)	(279.28)	(159.16)	(207.21)	(46.55)	6.01	(183.18)	(94.29)	(53.15)	(60.06)
	Cash flow	66.89	64.24	51.93	38.83	170.65	90.86	(4.10)	(45.34)	(7.01)	(9.58)
	Capex	(135.79)	(104.64)	(124.94)	(84.97)	(73.26)	(59.65)	(26.60)	(10.61)	(16.83)	(10.06)
	Free cash flow	(68.90)	(40.40)	(73.00)	(46.14)	97.39	31.21	(30.70)	(55.95)	(23.83)	(19.64)
	Book value	711.10	452.75	316.48	33.78	(15.94)	(2.19)	(9.68)	(93.95)	(58.82)	(116.36)
	Shares, m	0	0	0	0	0	0	0	0	1	1
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	20.41	0.00	0.00	0.00	0.00
	P/S	1.60	1.13	0.49	0.24	0.78	0.34	0.57	0.30	0.26	0.33
	P/B	1.47	1.72	1.09	4.57	0.00	0.00	0.00	0.00	0.00	0.00
	EV/Sales	1.76	1.49	1.02	1.19	1.51	1.12	1.62	1.42	1.80	3.31
	EV/FCF	(2.57)	(2.41)	(1.76)	(2.49)	(9.45)	(42.78)	(14.69)	(5.65)	(7.77)	(10.28)
Cash, $m
Cash, $m	Operating cash flow	10	9	7	5	24	13	(1)	(12)	(4)	(6)
	Capex	(21)	(15)	(17)	(12)	(10)	(9)	(6)	(3)	(10)	(6)
	Free cash flow	(11)	(6)	(10)	(6)	14	5	(7)	(14)	(14)	(12)
Balance, $m
Balance, $m	Working capital	108	91	69	52	56	(28)	29	24	9	(105)
	Total debt	93	94	82	102	101	99	72	66	98	135
	Net debt	16	36	52	86	74	73	66	62	93	130
	Shareholders’ equity	109	65	44	5	(2)	0	(2)	(24)	(35)	(72)
Returns, %
Returns, %	ROA	(32.82)	(18.20)	(12.82)	(20.45)	(4.89)	0.70	(38.87)	(31.70)	(39.07)	(35.86)
	ROIC	(19.95)	(23.21)	(13.15)	(16.66)	0.07	5.68	(19.06)	(44.62)	(22.84)	(16.99)
	ROE	(62.38)	(46.31)	(40.44)	(118.58)	(512.27)	(68.95)	3,287.29	183.87	107.52	69.76

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
WOK WORK Medical Technology Group LTD	$6.0M	—	—	—	—	−948.94% (below 0%: shrinking)	—	—	Compare
AMIX Autonomix Medical, Inc.	$5.7M	— (loss-making)	—	—	n/m	−36.10% (below 0%: shrinking)	—	0.00%	Compare
NVNO enVVeno Medical Corporation	$5.5M	— (loss-making)	— (loss-making)	+0.32% (above 0%: growing)	n/m	+4.60% (above 0%: growing)	0.00%	0.00%	Compare
CODX Co-Diagnostics, Inc.	$5.3M	— (loss-making)	— (loss-making)	+1.96% (above 0%: growing)	n/m	+17.47% (above 0%: growing)	72.73%	(3,733.17%)	Compare
TBIO Telesis Bio Inc.	$5.3M	— (loss-making)	— (loss-making)	−61.79% (below 0%: shrinking)	n/m	−17.96% (below 0%: shrinking)	64.43%	(349.74%)	Compare
VNRX VolitionRX Limited	$5.3M	— (loss-making)	— (loss-making)	−1.97% (below 0%: shrinking)	n/m	+18.58% (above 0%: growing)	100.00%	(1,042.39%)	Compare
TRIB Trinity Biotech PLC	$5.1M	— (loss-making)	— (loss-making)	+43.28% (above 0%: growing)	n/m	+75.24% (above 0%: growing)	35.43%	(24.53%)
VVOS Vivos Therapeutics, Inc.	$4.8M	— (loss-making)	— (loss-making)	+34.90% (above 0%: growing)	n/m	+16.44% (above 0%: growing)	57.31%	(93.63%)	Compare
INBS Intelligent Bio Solutions Inc.	$4.8M	— (loss-making)	5.4×	+51.10% (above 0%: growing)	n/m	−31.59% (below 0%: shrinking)	43.23%	(360.19%)	Compare
Median of peers	$5.3M	—	—	+1.14%	—	−6.68%	60.87%	(349.74%)

All 149 Medical Devices stocks →